PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29445512-2 2018 The eye disorder that is most frequently reported in the cancer chemotherapy is associated with the combination of tegafur/gimeracil/potassium oxonate (S-1). Tegafur 115-122 proteasome 26S subunit, non-ATPase 1 Homo sapiens 152-155 32793829-1 2020 S-1 is an anticancer agent that is comprised of tegafur, gimeracil, and oteracil potassium, and is widely used in various carcinomas including oral squamous cell carcinoma (OSCC). Tegafur 48-55 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 32483952-9 2020 Palliative chemotherapy with tegafur, gimeracil, and oteracil (S-1) was restarted, and local pain was subsequently ameliorated. Tegafur 29-36 proteasome 26S subunit, non-ATPase 1 Homo sapiens 63-66 31011915-1 2019 BACKGROUND: S-1 is an oral anticancer drug composed of tegafur (FT), which is a prodrug of 5-FU, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate. Tegafur 55-62 proteasome 26S subunit, non-ATPase 1 Homo sapiens 12-15 31011915-1 2019 BACKGROUND: S-1 is an oral anticancer drug composed of tegafur (FT), which is a prodrug of 5-FU, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate. Tegafur 64-66 proteasome 26S subunit, non-ATPase 1 Homo sapiens 12-15 30524750-1 2018 Background: S-1 (a combination of tegafur, gimeracil, and oteracil) is used to treat various cancers. Tegafur 34-41 proteasome 26S subunit, non-ATPase 1 Homo sapiens 12-15 29931401-0 2018 Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent, S-1. Tegafur 36-43 proteasome 26S subunit, non-ATPase 1 Homo sapiens 123-126 29931401-1 2018 PURPOSE: To establish a method for the measurement of 5-fluorouracil (5-FU), and tegafur (FT) in tear samples from patients treated with oral fluoropyrimidine anticancer agent S-1. Tegafur 81-88 proteasome 26S subunit, non-ATPase 1 Homo sapiens 176-179 29931401-1 2018 PURPOSE: To establish a method for the measurement of 5-fluorouracil (5-FU), and tegafur (FT) in tear samples from patients treated with oral fluoropyrimidine anticancer agent S-1. Tegafur 90-92 proteasome 26S subunit, non-ATPase 1 Homo sapiens 176-179 29931401-10 2018 The mean concentrations of 5-FU and FT in tears during S-1 treatment were 0.17 +- 0.11 and 1.94 +- 0.71 mug/mL, respectively. Tegafur 36-38 proteasome 26S subunit, non-ATPase 1 Homo sapiens 55-58 29191594-1 2017 INTRODUCTION: S-1 is an oral fluoropyrimidine-based combination of tegafur, gimeracil, and oteracil potassium. Tegafur 67-74 proteasome 26S subunit, non-ATPase 1 Homo sapiens 14-17 26715117-1 2017 BACKGROUND: Oral fluoropyrimidine S-1 contains tegafur, which is metabolized to 5-fluorouracil by cytochrome P450 2A6 (CYP2A6). Tegafur 47-54 proteasome 26S subunit, non-ATPase 1 Homo sapiens 34-37 28698442-1 2017 S-1 is an oral antineoplastic agent containing tegafur, gimeracil, and oteracil potassium. Tegafur 47-54 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 28159957-1 2017 Background: S-1 is a combination of tegafur [metabolized to 5-fluorouracil (5-FU)] with the modulators gimeracil (5-chloro-2,4-dihydroxypyridine) and oteracil potassium. Tegafur 36-43 proteasome 26S subunit, non-ATPase 1 Homo sapiens 12-15 28449472-3 2017 Patients received S-1 (tegafur/gimeracil/oteracil) and cisplatin at doses of 70 mg/m2/day for two weeks and 75 mg/m2 on day 1, respectively, every 3 weeks. Tegafur 23-30 proteasome 26S subunit, non-ATPase 1 Homo sapiens 18-21 27966431-1 2017 INTRODUCTION: The use of adjuvant chemotherapy with S-1 (tegafur, gimeracil, and oteracil potassium) has been shown to improve the outcome of patients with gastric cancer. Tegafur 57-64 proteasome 26S subunit, non-ATPase 1 Homo sapiens 52-55 25810324-1 2015 S-1 is an oral 5-fluorouracil agent containing tegafur, 5-chloro-2, 4-dihydroxypyridine (CDHP), and potassium oxonate. Tegafur 47-54 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 28496035-1 2017 S-1 is an anticancer agent that consists of tegafur, gimeracil, and oteracil potassium at a molar ratio of 1:0.4:1. Tegafur 44-51 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 27822036-3 2016 Recently, we have reported that metronomic S-1, orally available tegafur formulation, dosing synergistically augmented the therapeutic efficacy of oxaliplatin (l-OHP)-containing PEGylated liposome without increasing the toxicity in animal model. Tegafur 65-72 proteasome 26S subunit, non-ATPase 1 Homo sapiens 43-46 27980246-1 2017 S-1 is a new oral fluoropyrimidine formulation that comprises tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate. Tegafur 62-69 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 23998404-1 2013 BACKGROUND: Concurrent chemoradiotherapy using S-1 containing tegafur, an oral 5-FU prodrug, plus cisplatin has been reported to show promising efficacy against locally advanced non-small cell lung cancer with acceptable toxicity. Tegafur 62-69 proteasome 26S subunit, non-ATPase 1 Homo sapiens 47-50 25874010-1 2015 PURPOSE: The aim of this study was to clarify the risk factors for discontinuing tegafur/gimeracil/oteracil potassium (S-1) adjuvant chemotherapy following gastrectomy in patients with gastric cancer. Tegafur 81-88 proteasome 26S subunit, non-ATPase 1 Homo sapiens 119-122 25109221-1 2014 INTRODUCTION: S-1 is an oral fluoropyrimidine derivative, including three pharmacological compounds: tegafur, gimeracil and oteracil, in a molar ratio of 1: 0.4: 1. Tegafur 101-108 proteasome 26S subunit, non-ATPase 1 Homo sapiens 14-17 25032886-1 2014 INTRODUCTION: S-1 is an oral fluoropyrimidine that consists of tegafur, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate. Tegafur 63-70 proteasome 26S subunit, non-ATPase 1 Homo sapiens 14-17 23982118-8 2013 The exploratory pharmacokinetic/pharmacogenetic study showed that CYP2A6 variants (*4, *7, *9) are associated with a lower metabolic ratio of S-1 (exposure ratio of 5-fluorouracil to tegafur). Tegafur 183-190 proteasome 26S subunit, non-ATPase 1 Homo sapiens 142-145 22322240-1 2012 S-1 is an oral antitumor agent that contains tegafur, which is converted to fluorouracil (5-FU) in the human body. Tegafur 45-52 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 22860709-2 2012 S-1 , a fourth-generation oral fluoropyrimidine that combines tegafur and two biochemical modulators: gimeracil and oteracil potassium, is now attracting considerable interest. Tegafur 62-69 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 23710321-2 2013 Here, we report a case of advanced metastatic CBD cancer successfully treated by chemotherapy with gemcitabine combined with S-1 (tegafur+gimeracil+oteracil). Tegafur 130-137 proteasome 26S subunit, non-ATPase 1 Homo sapiens 125-128 23289150-1 2012 The study is to investigate the pharmacokinetics of S-1 capsule (tegafur, gimeracil and potassium oxonate capsule) in patients with advanced gastric cancer after single and multiple oral administration. Tegafur 65-72 proteasome 26S subunit, non-ATPase 1 Homo sapiens 52-55 20714726-1 2011 PURPOSE: To evaluate the efficacy, safety and pharmacokinetic profiles of S-1, which composed of tegafur (FT, a prodrug of 5-FU), 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), in Taiwanese advanced gastric cancer (AGC) patients. Tegafur 97-104 proteasome 26S subunit, non-ATPase 1 Homo sapiens 74-77 22241359-1 2012 The S-1(tegafur/gimeracil/oteracil potassium)granule was developed to meet the needs of patients with cancer. Tegafur 8-15 proteasome 26S subunit, non-ATPase 1 Homo sapiens 4-7 22251528-0 2012 Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil and oteracil potassium) for colorectal cancer. Tegafur 59-66 proteasome 26S subunit, non-ATPase 1 Homo sapiens 48-51 20714726-1 2011 PURPOSE: To evaluate the efficacy, safety and pharmacokinetic profiles of S-1, which composed of tegafur (FT, a prodrug of 5-FU), 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), in Taiwanese advanced gastric cancer (AGC) patients. Tegafur 106-108 proteasome 26S subunit, non-ATPase 1 Homo sapiens 74-77 19921195-1 2010 PURPOSE: S-1 is an oral anticancer drug containing tegafur (FT), a pro-drug of fluorouracil, combined with two modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), at a molar ratio of 1:0.4:1. Tegafur 51-58 proteasome 26S subunit, non-ATPase 1 Homo sapiens 9-12 21675835-8 2011 One oral fluoropyrimidine, S-1, is novel as it combines tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate. Tegafur 56-63 proteasome 26S subunit, non-ATPase 1 Homo sapiens 27-30 21487460-2 2011 We describe the case of a 76-year-old male showing transient effectiveness with an oral 5-fluorouracil derivative, S-1 (tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate), for epirubicin, cyclophosphamide and paclitaxel refractory skin metastases from possible occult breast cancer. Tegafur 120-127 proteasome 26S subunit, non-ATPase 1 Homo sapiens 115-118 22162925-1 2011 S-1 is a combination of three pharmacological compounds, namely tegafur, gimeracil, and oteracil potassium. Tegafur 64-71 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 20559897-1 2010 BACKGROUND: Irinotecan and S-1, an oral fluoropyrimidine composed of tegafur, gimeracil, and oteracil potassium, have demonstrated antitumor activity against advanced gastric cancer. Tegafur 69-76 proteasome 26S subunit, non-ATPase 1 Homo sapiens 27-30 19921195-1 2010 PURPOSE: S-1 is an oral anticancer drug containing tegafur (FT), a pro-drug of fluorouracil, combined with two modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), at a molar ratio of 1:0.4:1. Tegafur 60-62 proteasome 26S subunit, non-ATPase 1 Homo sapiens 9-12 19632949-1 2009 S-1 (also known as TS-1; Taiho Pharmaceutical Co. Ltd.; Tokyo, Japan) is a new oral fluoropyrimidine formulation that combines tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate in a molar ratio of 1:0.4:1. Tegafur 127-134 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 20424000-4 2010 We used 5-fluorouracil (5FU) instead of S-1 for in vitro experiments, given that tegafur, a component of S-1, is metabolized to 5FU in the liver. Tegafur 81-88 proteasome 26S subunit, non-ATPase 1 Homo sapiens 105-108 22966328-3 2010 An oral combined fluoropyrimidine drug, S-1 (tegafur, gimeracil and oteracil), has recently been introduced alone or in combination with gemcitabine for BDC. Tegafur 45-52 proteasome 26S subunit, non-ATPase 1 Homo sapiens 40-43 20414030-0 2010 [Successful management with S-1 of recurrent gastric cancer after adjuvant chemotherapy with paclitaxel/UFT]. Tegafur 104-107 proteasome 26S subunit, non-ATPase 1 Homo sapiens 28-31 19243284-2 2009 S-1 consists of tegafur, a prodrug of 5-FU combined with two 5-FU biochemical modulators:5-chloro-2,4-dihydroxypyridine (gimeracil or CDHP), a competitive inhibitor of dihydropyrimidine dehydrogenase and oteracil potassium which inhibits phosphorylation of 5-FU in the gastrointestinal tract decreasing serious gastrointestinal toxicities,including nausea, vomiting, stomatitis and diarrhea. Tegafur 16-23 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 19052037-5 2009 S-1 is an oral anticancer agent containing two biochemical modulators for 5-FU and tegafur (FT), a metabolically activated prodrug of 5-FU. Tegafur 83-90 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 16549996-2 2006 A single oral dose of S-1, 50 mg as tegafur, was administered, serial peripheral blood samples were collected, and the concentrations of 5-fluorouracil (5-FU) and gimeracil (CDHP) were measured. Tegafur 36-43 proteasome 26S subunit, non-ATPase 1 Homo sapiens 22-25 18383902-1 2008 S-1 is a novel oral anticancer drug, composed of tegafur (FT), gimestat (CDHP) and otastat potassium (Oxo), based on the biochemical modulation of 5-fluorouracil (5-FU). Tegafur 49-56 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 18383902-1 2008 S-1 is a novel oral anticancer drug, composed of tegafur (FT), gimestat (CDHP) and otastat potassium (Oxo), based on the biochemical modulation of 5-fluorouracil (5-FU). Tegafur 58-60 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 16786333-1 2007 PURPOSE: S-1 is a novel oral fluoropyrimidine that combines tegafur with CDHP and oxonic acid. Tegafur 60-67 proteasome 26S subunit, non-ATPase 1 Homo sapiens 9-12 16897985-10 2006 In addition, considerable ethnic differences in the tolerated doses of S-1 have been considered related to varying efficiency rates of conversion of tegafur to 5-fluorouracil by the CYP450 enzyme system. Tegafur 149-156 proteasome 26S subunit, non-ATPase 1 Homo sapiens 71-74 16897986-3 2006 S-1 is an oral 5-FU anti-tumor drug that combines three pharmacological agents: tegafur, 5-chloro-2,4-dihydroxypyridine, which inhibits dihydropyrimidine dehydrogenase activity, and potassium oxonate, which reduces gastrointestinal toxicity. Tegafur 80-87 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 15160338-1 2004 BACKGROUND: The goal of the current study was to evaluate the objective response rate and toxicity associated with the oral fluoropyrimidine S-1 (a combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) in patients with previously untreated metastatic colorectal carcinoma. Tegafur 163-170 proteasome 26S subunit, non-ATPase 1 Homo sapiens 141-144 15944764-1 2005 The purposes of this study were to evaluate the antitumor activity of S-1 (1 M tegafur, 0.4 M 5-chloro-2,4-dihydroxypyridine and 1 M potassium oxonate) on human lung tumor xenografts, as compared with other fluoro-pyrimidines, and to investigate the relationships between fluoropyrimidine antitumor activities and four distinct enzymatic activities involved in the phosphorylation and degradation pathways of 5-fluorouracil (5-FU) metabolism. Tegafur 79-86 proteasome 26S subunit, non-ATPase 1 Homo sapiens 70-73 15944764-4 2005 Cluster analysis, on the basis of antitumor activity, indicated that S-1/UFT and 5"-DFUR/capecitabine/5-FU could be classified into another group. Tegafur 73-76 proteasome 26S subunit, non-ATPase 1 Homo sapiens 69-72 15297391-1 2004 PURPOSE: The oral fluoropyrimidine S-1, which consists of a mixture of a 5-fluorouracil (5-FU) prodrug (tegafur), a dihydropyrimidine dehydrogenase inhibitor [5-chloro-2,4-dihydroxypyrimidine (CDHP)], and an inhibitor of orotate phosphoribosyltransferase [potassium oxonate (oxonic acid)], was developed to increase the feasibility and therapeutic index of 5-FU administered orally. Tegafur 104-111 proteasome 26S subunit, non-ATPase 1 Homo sapiens 35-38 15224197-0 2004 Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer. Tegafur 59-66 proteasome 26S subunit, non-ATPase 1 Homo sapiens 48-51 15075664-7 2004 This review will focus on the oral fluoropyrimidine S-1, which consists of the 5-FU prodrug tegafur (ftorafur, FT) and two enzyme inhibitors, i.e. CDHP (5-chloro-2,4-dihydroxypyridine) and OXO (potassium oxonate), in a molar ratio of 1(FT):0.4 (CDHP):1(OXO). Tegafur 92-99 proteasome 26S subunit, non-ATPase 1 Homo sapiens 52-55 15075664-7 2004 This review will focus on the oral fluoropyrimidine S-1, which consists of the 5-FU prodrug tegafur (ftorafur, FT) and two enzyme inhibitors, i.e. CDHP (5-chloro-2,4-dihydroxypyridine) and OXO (potassium oxonate), in a molar ratio of 1(FT):0.4 (CDHP):1(OXO). Tegafur 101-109 proteasome 26S subunit, non-ATPase 1 Homo sapiens 52-55 15550867-1 2004 BACKGROUND: S-1 is a newly developed novel oral dihydrouracil dehydrogenase inhibiting fluoropyrimidine drug consisting of 1 M tegafur (FT), 0.4 M 5-chloro-2, 4-dihydroxypyrimidine (gimeracil), and 1 M potassium oxonate (oteracil), with efficient antitumor activity and low gastrointestinal toxicity which is widely used in Japan against advanced gastric, head and neck cancers. Tegafur 127-134 proteasome 26S subunit, non-ATPase 1 Homo sapiens 12-15 15550867-1 2004 BACKGROUND: S-1 is a newly developed novel oral dihydrouracil dehydrogenase inhibiting fluoropyrimidine drug consisting of 1 M tegafur (FT), 0.4 M 5-chloro-2, 4-dihydroxypyrimidine (gimeracil), and 1 M potassium oxonate (oteracil), with efficient antitumor activity and low gastrointestinal toxicity which is widely used in Japan against advanced gastric, head and neck cancers. Tegafur 136-138 proteasome 26S subunit, non-ATPase 1 Homo sapiens 12-15 14663640-2 2003 S-1 is an oral fluoropyrimidine derivative combining tegafur with the modulators 5-chloro-2,4-dihydroxypyrimidine (a potent dihydropyrimidine dehydrogenase inhibitor), and potassium oxonate (an orotate phosphoribosyl transferase inhibitor), in a molar ratio of 1 : 0.4 : 1. Tegafur 53-60 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 15331922-1 2004 OBJECTIVE: S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), an inhibitor of dihydropyrimidine dehydrogenase, and potassium oxonate (Oxo), a reducer of gastrointestinal toxicity. Tegafur 103-110 proteasome 26S subunit, non-ATPase 1 Homo sapiens 11-14 15331922-1 2004 OBJECTIVE: S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), an inhibitor of dihydropyrimidine dehydrogenase, and potassium oxonate (Oxo), a reducer of gastrointestinal toxicity. Tegafur 112-114 proteasome 26S subunit, non-ATPase 1 Homo sapiens 11-14 12763215-2 2003 S-1 is a new oral fluorinated pyrimidine derivate, in which the oral 5-fluorouracil (5-FU) prodrug, tegafur, was combined with two 5-FU-modulating substances, 5-chloro-2,4-dihydroxypyridine (gimeracil), and potassium oxonate (oteracil), at a molar ratio of 1:0.4:1. Tegafur 100-107 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 14650374-1 2003 OBJECTIVE: S-1 is an oral anticancer agent combining tegafur (FT), a prodrug of 5-fluorouracil (5-FU), with potassium oxonate (oteracil) and gimeracil (CDHP) respectively to mitigate gastrointestinal toxicity and increase the half-life of 5-FU. Tegafur 53-60 proteasome 26S subunit, non-ATPase 1 Homo sapiens 11-14 14650374-1 2003 OBJECTIVE: S-1 is an oral anticancer agent combining tegafur (FT), a prodrug of 5-fluorouracil (5-FU), with potassium oxonate (oteracil) and gimeracil (CDHP) respectively to mitigate gastrointestinal toxicity and increase the half-life of 5-FU. Tegafur 62-64 proteasome 26S subunit, non-ATPase 1 Homo sapiens 11-14 12739060-1 2003 S-1 is an oral formulation of ftorafur (FT), oxonic acid and 5-chloro-2,4-dihydroxypyridine (CDHP) at a molar ratio of 1:0.4:1. Tegafur 30-38 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 12739060-1 2003 S-1 is an oral formulation of ftorafur (FT), oxonic acid and 5-chloro-2,4-dihydroxypyridine (CDHP) at a molar ratio of 1:0.4:1. Tegafur 40-42 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 12739060-8 2003 Cumulative urinary excretion of FT was predominantly as 5-FU and was 2.2-11.9%; the urinary excretion of both fluoro-beta-alanine and uracil was generally maximal between 6 and 18 h. During 28-day courses with twice-daily S-1 administration, 5-FU and uracil generally increased. Tegafur 32-34 proteasome 26S subunit, non-ATPase 1 Homo sapiens 222-225 12185293-13 2002 The second part is devoted to a review of the literature on three recent prodrugs of 5-FU, i.e., capecitabine, UFT (ftorafur [FTO] plus uracil), and S-1 (FTO plus 5-chloro-2,4-dihydroxypyridine plus potassium oxonate). Tegafur 154-157 proteasome 26S subunit, non-ATPase 1 Homo sapiens 149-152 12775012-2 2003 S-1 is a novel oral dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine (DIF) based on a biochemical modulation of 5-fluorouracil (5-FU); S-1 contains tegafur (FF) and two types of enzyme inhibitor, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1. Tegafur 165-172 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 12111108-1 2002 PURPOSE: S-1 is a novel oral fluorouracil antitumor drug that combines tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD), and potassium oxonate (Oxo). Tegafur 71-78 proteasome 26S subunit, non-ATPase 1 Homo sapiens 9-12 12111108-1 2002 PURPOSE: S-1 is a novel oral fluorouracil antitumor drug that combines tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD), and potassium oxonate (Oxo). Tegafur 80-82 proteasome 26S subunit, non-ATPase 1 Homo sapiens 9-12 12538461-1 2003 PURPOSE: Our purpose in the study was to determine the maximum tolerated dose and dose-limiting toxicity and investigate the clinical pharmacology of S-1, a combination of tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate. Tegafur 172-179 proteasome 26S subunit, non-ATPase 1 Homo sapiens 150-153 10901361-2 2000 This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted at inhibition of dihydropyrimidine dehydrogenase (DPD). Tegafur 131-138 proteasome 26S subunit, non-ATPase 1 Homo sapiens 111-114 11497250-1 2001 S-1 is a new oral formulation of 5-fluorouracil (5-FU) containing 1 M tegafur and 0.4 M 5-chloro-2,4-dihydroxypyridine (CDHP) and 1 M potassium oxonate (Oxo). Tegafur 70-77 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 10363584-0 1999 Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) on liver metastasis of xenotransplanted human colon carcinoma. Tegafur 26-33 proteasome 26S subunit, non-ATPase 1 Homo sapiens 94-97 10473078-1 1999 S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD) activity; and potassium oxonate (Oxo), which reduces gastrointestinal toxicity. Tegafur 92-99 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 10473078-1 1999 S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD) activity; and potassium oxonate (Oxo), which reduces gastrointestinal toxicity. Tegafur 101-103 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 10363584-1 1999 S-1 [1 M tegafur (FT)-0.4 M 5-chloro-2,4-dihydroxypyridine (CDHP)-1 M potassium oxonate (Oxo)], was developed as a new oral antineoplastic agent based on biochemical modulation of fluorouracil (5-FU) by CDHP and Oxo. Tegafur 9-16 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 10363584-1 1999 S-1 [1 M tegafur (FT)-0.4 M 5-chloro-2,4-dihydroxypyridine (CDHP)-1 M potassium oxonate (Oxo)], was developed as a new oral antineoplastic agent based on biochemical modulation of fluorouracil (5-FU) by CDHP and Oxo. Tegafur 18-20 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 9840729-2 1998 S-1 is an oral combined form of 1 M tegafur [a prodrug of 5-fluorouracil (5-FU)], 0.4 M 5-chloro-2,4-dihydroxypyridine (a reversible inhibitor of dihydropyrimidine dehydrogenase) and 1 M potassium oxonate (an inhibitor of orotate phosphoribosyltransferase). Tegafur 36-43 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 9893658-0 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Tegafur 76-83 proteasome 26S subunit, non-ATPase 1 Homo sapiens 67-70 9893658-1 1998 S-1 is a novel oral anticancer drug, composed of tegafur (FT), gimestat (CDHP) and otastat potassium (Oxo) in a molar ratio of 1:0.4:1, based on the biochemical modulation of 5-fluorouracil (5-FU). Tegafur 49-56 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 9893658-1 1998 S-1 is a novel oral anticancer drug, composed of tegafur (FT), gimestat (CDHP) and otastat potassium (Oxo) in a molar ratio of 1:0.4:1, based on the biochemical modulation of 5-fluorouracil (5-FU). Tegafur 58-60 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 9679577-3 1998 To achieve high activity and low toxicity, S-1 was designed, in which tegafur, prodrug of 5-FU, was combined with two classes of modulators. Tegafur 70-77 proteasome 26S subunit, non-ATPase 1 Homo sapiens 43-46 9140762-0 1997 Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. Tegafur 39-46 proteasome 26S subunit, non-ATPase 1 Homo sapiens 17-20 9140762-1 1997 A high-performance liquid chromatography (HPLC) and gas chromatography-negative ion chemical ionization mass spectrometry (GC-NICI-MS) method was developed for the analysis of the combined antitumor drug S-1 (tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and active metabolite 5-fluorouracil in human plasma and urine. Tegafur 209-216 proteasome 26S subunit, non-ATPase 1 Homo sapiens 204-207 9021668-1 1996 S-1 is a new antineoplastic agent of a fluorinated pyrimidine derivative containing tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1 with the aim of prolonging the effective plasma concentration of 5-fluorouracil (5-FU) and reducing its dose-limiting gastrointestinal toxicity. Tegafur 84-91 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 9021668-1 1996 S-1 is a new antineoplastic agent of a fluorinated pyrimidine derivative containing tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1 with the aim of prolonging the effective plasma concentration of 5-fluorouracil (5-FU) and reducing its dose-limiting gastrointestinal toxicity. Tegafur 93-95 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3